vs
Side-by-side financial comparison of ADMA BIOLOGICS, INC. (ADMA) and BLACKLINE, INC. (BL). Click either name above to swap in a different company.
BLACKLINE, INC. is the larger business by last-quarter revenue ($183.2M vs $139.2M, roughly 1.3× ADMA BIOLOGICS, INC.). ADMA BIOLOGICS, INC. runs the higher net margin — 35.5% vs 2.7%, a 32.8% gap on every dollar of revenue. On growth, ADMA BIOLOGICS, INC. posted the faster year-over-year revenue change (18.4% vs 8.1%). ADMA BIOLOGICS, INC. produced more free cash flow last quarter ($34.6M vs $26.1M). Over the past eight quarters, ADMA BIOLOGICS, INC.'s revenue compounded faster (30.4% CAGR vs 7.9%).
ADMA Biologics Inc. is a biopharmaceutical enterprise focused on the research, development, manufacturing and commercialization of specialty plasma-derived immunoglobulin therapies. It primarily operates in the United States, catering to patients with primary immunodeficiency and other immune-related disorders, healthcare providers and medical institutions across its core immune health therapeutic segment.
BlackLine Systems, Inc., is an American enterprise software company that develops cloud-based services designed to automate and manage the entire financial close process as well as consolidation, invoice-to-cash, and intercompany accounting. The Los Angeles–based company has 17 offices worldwide.
ADMA vs BL — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $139.2M | $183.2M |
| Net Profit | $49.4M | $4.9M |
| Gross Margin | 63.8% | 75.2% |
| Operating Margin | 45.1% | 3.7% |
| Net Margin | 35.5% | 2.7% |
| Revenue YoY | 18.4% | 8.1% |
| Net Profit YoY | -55.9% | -91.3% |
| EPS (diluted) | $0.20 | $0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $139.2M | $183.2M | ||
| Q3 25 | $134.2M | $178.3M | ||
| Q2 25 | $122.0M | $172.0M | ||
| Q1 25 | $114.8M | $166.9M | ||
| Q4 24 | $117.5M | $169.5M | ||
| Q3 24 | $119.8M | $165.9M | ||
| Q2 24 | $107.2M | $160.5M | ||
| Q1 24 | $81.9M | $157.5M |
| Q4 25 | $49.4M | $4.9M | ||
| Q3 25 | $36.4M | $5.3M | ||
| Q2 25 | $34.2M | $8.3M | ||
| Q1 25 | $26.9M | $6.1M | ||
| Q4 24 | $111.9M | $56.4M | ||
| Q3 24 | $35.9M | $17.2M | ||
| Q2 24 | $32.1M | $76.7M | ||
| Q1 24 | $17.8M | $10.8M |
| Q4 25 | 63.8% | 75.2% | ||
| Q3 25 | 56.3% | 75.1% | ||
| Q2 25 | 55.1% | 75.2% | ||
| Q1 25 | 53.2% | 75.5% | ||
| Q4 24 | 53.9% | 75.6% | ||
| Q3 24 | 49.8% | 75.2% | ||
| Q2 24 | 53.6% | 74.9% | ||
| Q1 24 | 47.8% | 75.2% |
| Q4 25 | 45.1% | 3.7% | ||
| Q3 25 | 38.0% | 4.3% | ||
| Q2 25 | 35.1% | 4.4% | ||
| Q1 25 | 30.4% | 2.1% | ||
| Q4 24 | 32.6% | 3.7% | ||
| Q3 24 | 33.1% | 5.0% | ||
| Q2 24 | 36.6% | 1.4% | ||
| Q1 24 | 26.7% | 1.1% |
| Q4 25 | 35.5% | 2.7% | ||
| Q3 25 | 27.1% | 3.0% | ||
| Q2 25 | 28.1% | 4.8% | ||
| Q1 25 | 23.4% | 3.6% | ||
| Q4 24 | 95.2% | 33.3% | ||
| Q3 24 | 30.0% | 10.4% | ||
| Q2 24 | 29.9% | 47.8% | ||
| Q1 24 | 21.7% | 6.9% |
| Q4 25 | $0.20 | $0.07 | ||
| Q3 25 | $0.15 | $0.09 | ||
| Q2 25 | $0.14 | $0.13 | ||
| Q1 25 | $0.11 | $0.10 | ||
| Q4 24 | $0.45 | $0.79 | ||
| Q3 24 | $0.15 | $0.27 | ||
| Q2 24 | $0.13 | $0.22 | ||
| Q1 24 | $0.08 | $0.17 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $87.6M | $390.0M |
| Total DebtLower is stronger | $72.1M | — |
| Stockholders' EquityBook value | $477.3M | $332.3M |
| Total Assets | $624.2M | $1.8B |
| Debt / EquityLower = less leverage | 0.15× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $87.6M | $390.0M | ||
| Q3 25 | $61.4M | $419.9M | ||
| Q2 25 | $90.3M | $459.1M | ||
| Q1 25 | $71.6M | $479.5M | ||
| Q4 24 | $103.1M | $885.9M | ||
| Q3 24 | $86.7M | $725.3M | ||
| Q2 24 | $88.2M | $616.6M | ||
| Q1 24 | $45.3M | $331.4M |
| Q4 25 | $72.1M | — | ||
| Q3 25 | $72.4M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $72.3M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $477.3M | $332.3M | ||
| Q3 25 | $431.2M | $328.3M | ||
| Q2 25 | $398.3M | $414.0M | ||
| Q1 25 | $373.4M | $417.9M | ||
| Q4 24 | $349.0M | $446.7M | ||
| Q3 24 | $231.9M | $367.9M | ||
| Q2 24 | $188.3M | $325.8M | ||
| Q1 24 | $153.7M | $279.8M |
| Q4 25 | $624.2M | $1.8B | ||
| Q3 25 | $568.7M | $1.7B | ||
| Q2 25 | $558.4M | $1.8B | ||
| Q1 25 | $510.6M | $1.8B | ||
| Q4 24 | $488.7M | $1.8B | ||
| Q3 24 | $390.6M | $1.7B | ||
| Q2 24 | $376.4M | $1.9B | ||
| Q1 24 | $350.9M | $2.1B |
| Q4 25 | 0.15× | — | ||
| Q3 25 | 0.17× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.21× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $35.6M | $26.7M |
| Free Cash FlowOCF − Capex | $34.6M | $26.1M |
| FCF MarginFCF / Revenue | 24.8% | 14.2% |
| Capex IntensityCapex / Revenue | 0.8% | 0.3% |
| Cash ConversionOCF / Net Profit | 0.72× | 5.46× |
| TTM Free Cash FlowTrailing 4 quarters | $27.8M | $161.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $35.6M | $26.7M | ||
| Q3 25 | $13.3M | $63.8M | ||
| Q2 25 | $21.1M | $32.3M | ||
| Q1 25 | $-19.7M | $46.7M | ||
| Q4 24 | $50.2M | $43.8M | ||
| Q3 24 | $25.0M | $55.9M | ||
| Q2 24 | $45.6M | $40.7M | ||
| Q1 24 | $-2.2M | $50.4M |
| Q4 25 | $34.6M | $26.1M | ||
| Q3 25 | $-1.1M | $63.3M | ||
| Q2 25 | $18.7M | $31.4M | ||
| Q1 25 | $-24.4M | $40.8M | ||
| Q4 24 | $47.5M | $43.0M | ||
| Q3 24 | $24.0M | $55.5M | ||
| Q2 24 | $43.6M | $40.0M | ||
| Q1 24 | $-4.6M | $50.1M |
| Q4 25 | 24.8% | 14.2% | ||
| Q3 25 | -0.8% | 35.5% | ||
| Q2 25 | 15.3% | 18.2% | ||
| Q1 25 | -21.2% | 24.4% | ||
| Q4 24 | 40.4% | 25.4% | ||
| Q3 24 | 20.0% | 33.5% | ||
| Q2 24 | 40.7% | 24.9% | ||
| Q1 24 | -5.6% | 31.8% |
| Q4 25 | 0.8% | 0.3% | ||
| Q3 25 | 10.7% | 0.3% | ||
| Q2 25 | 2.0% | 0.6% | ||
| Q1 25 | 4.1% | 3.6% | ||
| Q4 24 | 2.3% | 0.4% | ||
| Q3 24 | 0.9% | 0.2% | ||
| Q2 24 | 1.9% | 0.4% | ||
| Q1 24 | 2.9% | 0.2% |
| Q4 25 | 0.72× | 5.46× | ||
| Q3 25 | 0.36× | 12.07× | ||
| Q2 25 | 0.62× | 3.90× | ||
| Q1 25 | -0.73× | 7.72× | ||
| Q4 24 | 0.45× | 0.78× | ||
| Q3 24 | 0.70× | 3.24× | ||
| Q2 24 | 1.42× | 0.53× | ||
| Q1 24 | -0.12× | 4.66× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ADMA
| ADMA Bio Manufacturing Segment | $123.1M | 88% |
| Other | $16.0M | 12% |
BL
| Subscription And Circulation | $173.2M | 95% |
| Technology Service | $10.0M | 5% |
